Decision to fund rasagiline

PHARMAC

16 July 2021 - PHARMAC is pleased to announce the decision to fund rasagiline (Azilect) a new treatment for people with Parkinson’s disease from 1 August 2021 through an agreement with Teva Pharma. 

Rasagiline will be fully funded for people without restriction.

Read PHARMAC press release

Michael Wonder

Posted by:

Michael Wonder